STOCK TITAN

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced that CEO Jacob M. Chacko, M.D. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The company focuses on developing treatments for therapeutic resistance in oncology. A live webcast of the presentation will be available on the company's website.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT.

A live webcast of the company presentation will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcast will be available for 90 days following the events.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com


FAQ

When is ORIC Pharmaceuticals, Inc. presenting at the 42nd Annual J.P. Morgan Healthcare Conference?

ORIC Pharmaceuticals, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024.

What is the focus of ORIC Pharmaceuticals, Inc.?

ORIC Pharmaceuticals, Inc. focuses on developing treatments for therapeutic resistance in oncology.

Where can I watch the live webcast of ORIC Pharmaceuticals, Inc.'s presentation?

The live webcast of the company presentation will be available through the investor section of the company’s website at www.oricpharma.com.

How long will the replays of the webcast be available?

Replays of the webcast will be available for 90 days following the events.

Oric Pharmaceuticals, Inc.

NASDAQ:ORIC

ORIC Rankings

ORIC Latest News

ORIC Stock Data

550.42M
59.77M
9.4%
102.1%
16.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO